RAPT RAPT Therapeutics

RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board

RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board
EN
14/10/2020

Underlying

RAPTRAPT Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPT Therapeutics

 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Rec...

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $250 million public offering to strengthen balance sheet SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based b...

November 6, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Participate in Multiple Upcoming Investor Confere...

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in November: Guggenheim's 2nd Annual Healthcare Innovation Conference – Fireside chat on Tuesday, November ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozurep...

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for ...

October 27, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share. In addition, RAPT has granted the underwriters a 30-day option to ...

October 22, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

RAPT Therapeutics Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, RAPT expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total...

October 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch